Endocrinol Metab.  2022 Feb;37(1):1-8. 10.3803/EnM.2022.101.

The Influence of Obesity and Metabolic Health on Vascular Health

• Rhee EJ

• KMID: 2527132
• DOI: http://doi.org/10.3803/EnM.2022.101

Abstract

The prevalence of obesity is rapidly increasing worldwide. Obesity should not be understood only as the accumulation of fat in the body, but instead as a phenomenon that exerts different effects on our health according to the place of fat deposition and its stability. Obesity is the starting point of most metabolic diseases, such as diabetes, hypertension, metabolic syndrome, sleep apnea, and eventually cardiovascular disease. There are different kinds of obesity, ranging from simple obesity to sarcopenic obesity. The main purpose of intervening to address obesity is to decrease the ultimate consequence of obesity—namely, cardiovascular disease. The main mechanism through which obesity, especially abdominal obesity, increases cardiovascular risk is the obesity-induced derangement of metabolic health, leading to the development of metabolic diseases such as diabetes, non-alcoholic fatty liver disease, and metabolic syndrome, which are the main initiators of vascular damage. In this review, I discuss the influence of various types of obesity on the risk of metabolic diseases, and how these diseases increase cardiovascular disease risk.

Keyword

Atherosclerosis; Cardiovascular diseases; Diabetes mellitus; Metabolism; Obesity; Vascular calcification

Figure

• 

  Fig. 1 Obesity and its associations with metabolic diseases and vascular health.

Reference

1. World Health Organization. Overweight and obesity [Internet]. Geneva: WHO;2021. [cited 2022 Jan 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight .

2. Jarolimova J, Tagoni J, Stern TA. Obesity: its epidemiology, comorbidities, and management. Prim Care Companion CNS Disord. 2013; 15:PCC.12f01475.

3. Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015; 95:727–48.

4. Nam GE, Kim YH, Han K, Jung JH, Rhee EJ, Lee WY, et al. Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018. J Obes Metab Syndr. 2021; 30:141–8.

5. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016; 118:1723–35.

6. Lim S. Ectopic fat assessment focusing on cardiometabolic and renal risk. Endocrinol Metab (Seoul). 2014; 29:1–4.

7. Bays HE. “Sick fat,” metabolic disease, and atherosclerosis”. Am J Med. 2009; 122(1 Suppl):S26–37.

8. Lee YH, Han K, Ko SH, Ko KS, Lee KU; Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Data analytic process of a nationwide population-based study using national health information database established by National Health Insurance Service. Diabetes Metab J. 2016; 40:79–82.

9. Jung CH, Son JW, Kang S, Kim WJ, Kim HS, Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021; 45:1–10.

10. Kim HC, Cho SMJ, Lee H, Lee HH, Baek J, Heo JE, et al. Korea hypertension fact sheet 2020: analysis of nationwide population-based data. Clin Hypertens. 2021; 27:8.

11. Rhee EJ. Prevalence and current management of cardiovascular risk factors in Korean adults based on fact sheets. Endocrinol Metab (Seoul). 2020; 35:85–94.

12. Korean Diabetes Association. Diabetes Fact Sheet in Korea [Internet]. Seoul: KDA;2019. [cited 2022 Jan 25]. Available from: https://www.diabetes.or.kr/pro/news/admin.php?category=A&code=admin&mode=view&number=1788 .

13. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365:1415–28.

14. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–5.

15. Brown WV. Different definitions of the metabolic syndrome and risk for recurrent cardiovascular disease. Nat Clin Pract Endocrinol Metab. 2006; 2:492–3.

16. Lee WY, Park JS, Noh SY, Rhee EJ, Kim SW, Zimmet PZ. Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diabetes Res Clin Pract. 2004; 65:143–9.

17. Kondo T, Osugi S, Shimokata K, Honjo H, Morita Y, Yamashita K, et al. Metabolic syndrome and all-cause mortality, cardiac events, and cardiovascular events: a follow-up study in 25,471 young- and middle-aged Japanese men. Eur J Cardiovasc Prev Rehabil. 2011; 18:574–80.

18. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004; 173:309–14.

19. Sung KC, Rhee EJ, Ryu S, Kim BJ, Kim BS, Lee WY, et al. Increased cardiovascular mortality in subjects with metabolic syndrome is largely attributable to diabetes and hypertension in 159,971 Korean adults. J Clin Endocrinol Metab. 2015; 100:2606–12.

20. Seo MH, Rhee EJ. Metabolic and cardiovascular implications of a metabolically healthy obesity phenotype. Endocrinol Metab (Seoul). 2014; 29:427–34.

21. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation. 1995; 92:2157–62.

22. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008; 358:1336–45.

23. Blankstein R, Gupta A, Rana JS, Nasir K. The implication of coronary artery calcium testing for cardiovascular disease prevention and diabetes. Endocrinol Metab (Seoul). 2017; 32:47–57.

24. Rhee EJ, Seo MH, Kim JD, Jeon WS, Park SE, Park CY, et al. Metabolic health is more closely associated with coronary artery calcification than obesity. PLoS One. 2013; 8:e74564.

25. Rhee EJ, Lee MK, Kim JD, Jeon WS, Bae JC, Park SE, et al. Metabolic health is a more important determinant for diabetes development than simple obesity: a 4-year retrospective longitudinal study. PLoS One. 2014; 9:e98369.

26. Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019; 129:3978–89.

27. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002; 1:1.

28. Rhee EJ, Park SE, Chang Y, Ryu S, Lee WY. Baseline glycemic status and mortality in 241,499 Korean metropolitan subjects: a Kangbuk Samsung Health Study. Metabolism. 2016; 65:68–77.

29. Rhee EJ, Kim JH, Park HJ, Park SE, Oh HG, Park CY, et al. Increased risk for development of coronary artery calcification in insulin-resistant subjects who developed diabetes: 4-year longitudinal study. Atherosclerosis. 2016; 245:132–8.

30. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89:2548–56.

31. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66:1138–53.

32. Rhee EJ. Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective. Endocrinol Metab (Seoul). 2019; 34:226–33.

33. Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S, Lee WY. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis. Endocrinol Metab (Seoul). 2020; 35:165–76.

34. Rhee EJ, Lee WY, Cho YK, Kim BI, Sung KC. Hyperinsulinemia and the development of nonalcoholic fatty liver disease in nondiabetic adults. Am J Med. 2011; 124:69–76.

35. Lee DY, Rhee EJ, Chang Y, Sohn CI, Shin HC, Ryu S, et al. Impact of systemic inflammation on the relationship between insulin resistance and all-cause and cancer-related mortality. Metabolism. 2018; 81:52–62.

36. Lee SH, Kim MK, Rhee EJ. Effects of cardiovascular risk factor variability on health outcomes. Endocrinol Metab (Seoul). 2020; 35:217–26.

37. Rhee EJ, Han K, Ko SH, Ko KS, Lee WY. Increased risk for diabetes development in subjects with large variation in total cholesterol levels in 2,827,950 Koreans: a nationwide population-based study. PLoS One. 2017; 12:e0176615.

38. Rhee EJ, Cho JH, Kwon H, Park SE, Park CY, Oh KW, et al. Increased risk of diabetes development in individuals with weight cycling over 4 years: the Kangbuk Samsung Health study. Diabetes Res Clin Pract. 2018; 139:230–8.

39. Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications. 2002; 16:313–20.

40. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care. 2004; 27:1259–64.

41. Rhee EJ, Cho JH, Kwon H, Park SE, Park CY, Oh KW, et al. Association between coronary artery calcification and the hemoglobin glycation index: the Kangbuk Samsung Health Study. J Clin Endocrinol Metab. 2017; 102:4634–41.

42. Rhee EJ, Kwon H, Park SE, Han KD, Park YG, Kim YH, et al. Associations among obesity degree, glycemic status, and risk of heart failure in 9,720,220 Korean adults. Diabetes Metab J. 2020; 44:592–601.

43. Rhee SY, Han KD, Kwon H, Park SE, Park YG, Kim YH, et al. Association between glycemic status and the risk of Parkinson disease: a nationwide population-based study. Diabetes Care. 2020; 43:2169–75.